Geode Capital Management LLC Acquires 144,838 Shares of Hologic, Inc. (NASDAQ:HOLX)

Geode Capital Management LLC boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,732,131 shares of the medical equipment provider's stock after buying an additional 144,838 shares during the quarter. Geode Capital Management LLC owned 2.54% of Hologic worth $412,159,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of HOLX. National Bank of Canada FI boosted its position in shares of Hologic by 36.2% in the 4th quarter. National Bank of Canada FI now owns 260,002 shares of the medical equipment provider's stock valued at $18,749,000 after purchasing an additional 69,090 shares during the period. Rodgers Brothers Inc. raised its stake in shares of Hologic by 2.3% during the 4th quarter. Rodgers Brothers Inc. now owns 105,096 shares of the medical equipment provider's stock worth $7,576,000 after purchasing an additional 2,315 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Hologic by 27.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,687,347 shares of the medical equipment provider's stock worth $121,641,000 after purchasing an additional 361,539 shares in the last quarter. Allstate Corp acquired a new stake in shares of Hologic in the fourth quarter worth about $514,000. Finally, DnB Asset Management AS boosted its stake in shares of Hologic by 16.9% during the 4th quarter. DnB Asset Management AS now owns 246,285 shares of the medical equipment provider's stock worth $17,755,000 after acquiring an additional 35,662 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Hologic Stock Down 4.1 %

Shares of NASDAQ HOLX traded down $2.46 during mid-day trading on Thursday, hitting $56.85. The company had a trading volume of 935,184 shares, compared to its average volume of 2,622,222. The firm has a 50-day simple moving average of $63.03 and a two-hundred day simple moving average of $71.87. Hologic, Inc. has a one year low of $56.74 and a one year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $12.76 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Needham & Company LLC downgraded shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective for the company. in a report on Monday, February 3rd. Argus lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Leerink Partners downgraded shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Hologic currently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.